Chemotherapy for small cell lung cancer: a comprehensive review

about

Medicare Beneficiaries With Advanced Lung Cancer Experience Diverse Patterns Of Care From Diagnosis To Death.Proton therapy for small cell lung cancer.

P2860

Q38692292-329C2741-DEB6-40FA-8E1D-2F87FE59EE6D Q55358944-FBB186B5-ED18-4089-84F3-382B9670A3ED

P2860

Chemotherapy for small cell lung cancer: a comprehensive review

Item

http://www.wikidata.org/entity/Q35569379

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Chemotherapy for small cell lung cancer: a comprehensive review

@ast

Chemotherapy for small cell lung cancer: a comprehensive review

@en

type

Item

label

Chemotherapy for small cell lung cancer: a comprehensive review

@ast

Chemotherapy for small cell lung cancer: a comprehensive review

@en

prefLabel

Chemotherapy for small cell lung cancer: a comprehensive review

@ast

Chemotherapy for small cell lung cancer: a comprehensive review

@en

P1476

Chemotherapy for small cell lung cancer: a comprehensive review

@en

P2093

Jamal Zekri

http://www.w3.org/2001/XMLSchema#string

Syed Mustafa Karim

http://www.w3.org/2001/XMLSchema#string

P2860

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Thalidomide is an inhibitor of angiogenesis

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501

Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4081/ONCOL.2012.E4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259483675

http://www.w3.org/2001/XMLSchema#string

P698

25992206

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

4419639

http://www.w3.org/2001/XMLSchema#string

Chemotherapy for small cell lung cancer: a comprehensive review

about

P2860

P2860

Chemotherapy for small cell lung cancer: a comprehensive review

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932